Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

1.

Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.

Jacobs C, Kim DW, Straka C, Timmerman RD, Brugarolas J.

J Clin Oncol. 2013 Mar 1;31(7):e114-7. doi: 10.1200/JCO.2012.46.0501. Epub 2013 Jan 14. No abstract available.

PMID:
23319695
[PubMed - indexed for MEDLINE]
Free Article
2.

Pazopanib.

Bukowski RM, Yasothan U, Kirkpatrick P.

Nat Rev Drug Discov. 2010 Jan;9(1):17-8. doi: 10.1038/nrd3073.

PMID:
20043026
[PubMed - indexed for MEDLINE]
3.

[First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].

Maráz A, Bodrogi I, Csejtei A, Dank M, Géczi L, Küronya Z, Mangel L, Petrányi A, Szûcs M, Bodoky G.

Magy Onkol. 2013 Sep;57(3):173-6. doi: MagyOnkol.2013.57.3.173. Epub 2013 Aug 9. Hungarian.

PMID:
24107823
[PubMed - indexed for MEDLINE]
Free Article
4.

Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib.

Ratta R, Santini D.

Tumori. 2014 Mar-Apr;100(2):e59-62. doi: 10.1700/1491.16441.

PMID:
24852879
[PubMed - indexed for MEDLINE]
5.

Pazopanib for the treatment of metastatic renal cell carcinoma.

Pick AM, Nystrom KK.

Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16. Review.

PMID:
22341567
[PubMed - indexed for MEDLINE]
6.

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID.

Eur J Cancer. 2013 Apr;49(6):1287-96. doi: 10.1016/j.ejca.2012.12.010. Epub 2013 Jan 12.

PMID:
23321547
[PubMed - indexed for MEDLINE]
7.

Pazopanib: therapeutic developments.

Limvorasak S, Posadas EM.

Expert Opin Pharmacother. 2009 Dec;10(18):3091-102. doi: 10.1517/14656560903436493. Review.

PMID:
19954277
[PubMed - indexed for MEDLINE]
8.

[Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma].

Büchler T, Finek J, Hájek J, Kocák I, Kubácková K, Lakomý R, Melichar B, Petruzelka L, Poprach A, Siffnerová M, Tomásek J, Vyzula R, Zemanová M; Cezkou Kooperativní Skupinu pro Metastický Renální Karcinom.

Klin Onkol. 2013;26(1):55-7. Czech. No abstract available.

PMID:
23607143
[PubMed - indexed for MEDLINE]
9.

Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.

Bourdeanu L, Twardowski P, Pal SK.

Clin J Oncol Nurs. 2011 Oct;15(5):513-7. doi: 10.1188/11.CJON.513-517.

PMID:
21951737
[PubMed - indexed for MEDLINE]
10.

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.

Lee JL, Park I, Park K, Park S, Ahn Y, Ahn JH, Kim TW, Ahn S, Song C, Hong JH, Kim CS, Ahn H.

J Cancer Res Clin Oncol. 2012 Apr;138(4):687-93. doi: 10.1007/s00432-012-1148-8. Epub 2012 Jan 12.

PMID:
22237457
[PubMed - indexed for MEDLINE]
11.

Nursing considerations for patients receiving pazopanib for renal cell carcinoma.

Becze E.

ONS Connect. 2012 Feb;27(2):16-7. No abstract available.

PMID:
22375508
[PubMed - indexed for MEDLINE]
12.

Pazopanib in renal cell carcinoma.

Sternberg CN.

Clin Adv Hematol Oncol. 2010 Apr;8(4):232-3. No abstract available.

PMID:
20505644
[PubMed - indexed for MEDLINE]
13.

[Pharmacological sheet: pazopanib (Votrient), oral administration].

[No authors listed]

J Pharm Belg. 2011 Sep;(3):95-6. French. No abstract available.

PMID:
21995103
[PubMed - indexed for MEDLINE]
14.

Complete cerebral response with sunitinib for metastatic renal cell carcinoma.

Medioni J, Cojocarasu O, Belcaceres JL, Halimi P, Oudard S.

Ann Oncol. 2007 Jul;18(7):1282-3. No abstract available.

PMID:
17675397
[PubMed - indexed for MEDLINE]
Free Article
15.

Reversible posterior leukoencephalopathy syndrome induced by pazopanib.

Chelis L, Souftas V, Amarantidis K, Xenidis N, Chamalidou E, Dimopoulos P, Michailidis P, Christakidis E, Prassopoulos P, Kakolyris S.

BMC Cancer. 2012 Oct 22;12:489. doi: 10.1186/1471-2407-12-489.

PMID:
23088634
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.

Bonate PL, Suttle AB.

Cancer Chemother Pharmacol. 2013 Jul;72(1):231-40. doi: 10.1007/s00280-013-2191-0. Epub 2013 May 29.

PMID:
23715625
[PubMed - indexed for MEDLINE]
17.

Concise drug review: pazopanib and axitinib.

van Geel RM, Beijnen JH, Schellens JH.

Oncologist. 2012;17(8):1081-9. doi: 10.1634/theoncologist.2012-0055. Epub 2012 Jun 25. Review.

PMID:
22733795
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.

Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA.

J Clin Oncol. 2010 Jan 20;28(3):475-80. doi: 10.1200/JCO.2008.21.6994. Epub 2009 Dec 14.

PMID:
20008644
[PubMed - indexed for MEDLINE]
Free Article
19.

Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.

Zivi A, Cerbone L, Recine F, Sternberg CN.

Expert Opin Drug Saf. 2012 Sep;11(5):851-9. doi: 10.1517/14740338.2012.712108. Epub 2012 Aug 4. Review.

PMID:
22861374
[PubMed - indexed for MEDLINE]
20.

Successful treatment of a brain-metastasized renal cell carcinoma.

Walid MS, Johnston KW.

Ger Med Sci. 2009 Oct 21;7:Doc28. doi: 10.3205/000087.

PMID:
19911072
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk